Stock Scorer

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc. reported revenue of 733K USD for the quarter ending 30 June 2026, down 88.3% from 6.3M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 733K -88.3%
Operating Income Q2 '26 · ending 30 June 2026 -15.7M —
Net Income Q2 '26 · ending 30 June 2026 -15M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -17.6M —
Free Cash Flow Q4 '25 · ending 31 December 2025 -10.4M —
Shares Outstanding Q3 '24 · ending 30 September 2024 71M +0.6%
EPS Q3 '24 · ending 30 September 2024 -0.47 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 7.3M-42.4M-17.4M-38.3M
20242024-12-31 566K-61.9M-26.4M-56M
20232023-12-31 392K-59.3M-52.3M-45.8M
20222022-12-31 1.5M-55.5M-54.2M-56.5M
20212021-12-31 208.4M124.2M122.8M118.4M
20202020-12-31 12.6M-81.4M-81M-51.7M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30733K
Q1 '262026-03-310
Q4 '252025-12-31718K
Q3 '252025-09-30132K
Q2 '252025-06-306.3M
Q1 '252025-03-31130K
Q4 '242024-12-3176K
Q3 '242024-09-30173K
Q2 '242024-06-30169K
Q1 '242024-03-31148K
Q4 '232023-12-31142K
Q3 '232023-09-30109K
Q2 '232023-06-3075K
Q1 '232023-03-3166K
Q4 '222022-12-3146.3K
Q3 '222022-09-3011.1K
Q2 '222022-06-300
Q1 '222022-03-311.4M
Q4 '212021-12-310
Q3 '212021-09-300

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-15.7M
Q1 '262026-03-31-17.8M
Q4 '252025-12-31-12.3M
Q3 '252025-09-30-12.5M
Q2 '252025-06-30-5.1M
Q1 '252025-03-31-12.6M
Q4 '242024-12-31-10.7M
Q3 '242024-09-30-13.2M
Q2 '242024-06-30-20.5M
Q1 '242024-03-31-17.4M
Q4 '232023-12-31-18.2M
Q3 '232023-09-30-12M
Q2 '232023-06-30-14.2M
Q1 '232023-03-31-14.9M
Q4 '222022-12-31-12.2M
Q3 '222022-09-30-12.8M
Q2 '222022-06-30-14.3M
Q1 '222022-03-31-16.3M
Q4 '212021-12-31-26.4M
Q3 '212021-09-30-11.7M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-15M
Q1 '262026-03-31-17M
Q4 '252025-12-319.7M
Q3 '252025-09-30-12.2M
Q2 '252025-06-30-4.7M
Q1 '252025-03-31-10.2M
Q4 '242024-12-31-9.3M
Q3 '242024-09-30-14M
Q2 '242024-06-308.5M
Q1 '242024-03-31-11.7M
Q4 '232023-12-31-15.3M
Q3 '232023-09-30-11.3M
Q2 '232023-06-30-12.4M
Q1 '232023-03-31-13.4M
Q4 '222022-12-31-11.5M
Q3 '222022-09-30-12M
Q2 '222022-06-30-14.6M
Q1 '222022-03-31-16.1M
Q4 '212021-12-31-26M
Q3 '212021-09-30-11.4M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-17.6M
Q1 '262026-03-31-13.9M
Q4 '252025-12-31-10.4M
Q3 '252025-09-30-12.9M
Q2 '252025-06-30-4.8M
Q1 '252025-03-31-10.3M
Q4 '242024-12-31-10M
Q3 '242024-09-30-15M
Q2 '242024-06-30-14.3M
Q1 '242024-03-31-16.7M
Q4 '232023-12-31-11.9M
Q3 '232023-09-30-10.1M
Q2 '232023-06-30-11.7M
Q1 '232023-03-31-12.1M
Q4 '222022-12-31-9.2M
Q3 '222022-09-30-12.7M
Q2 '222022-06-30-13.3M
Q1 '222022-03-31-20.1M
Q4 '212021-12-31-12M
Q3 '212021-09-30-10.9M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-10.4M
Q3 '252025-09-30-12.9M
Q2 '252025-06-30-4.8M
Q1 '252025-03-31-10.3M
Q4 '242024-12-31-10M
Q3 '242024-09-30-15M
Q2 '242024-06-30-14.3M
Q1 '242024-03-31-16.7M
Q4 '232023-12-31-11.9M
Q3 '232023-09-30-10.1M
Q2 '232023-06-30-11.7M
Q1 '232023-03-31-12.1M
Q4 '222022-12-31-9.3M
Q3 '222022-09-30-12.7M
Q2 '222022-06-30-14.3M
Q1 '222022-03-31-20.1M
Q4 '212021-12-31-12.2M
Q3 '212021-09-30-10.9M
Q2 '212021-06-30-19.4M
Q1 '212021-03-31160.9M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q3 '242024-09-3071M
Q2 '242024-06-3071.2M
Q1 '242024-03-3170.7M
Q3 '232023-09-3070.6M
Q2 '232023-06-3070.5M
Q1 '232023-03-3170.5M
Q3 '222022-09-3070.4M
Q2 '222022-06-3070.4M
Q1 '222022-03-3170.3M
Q3 '212021-09-3067.9M
Q2 '212021-06-3067.8M
Q1 '212021-03-3166.6M
Q3 '202020-09-3059.4M
Q2 '202020-06-3055.6M
Q1 '202020-03-3154.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '242024-09-30-0.47
Q2 '242024-06-30-0.43
Q1 '242024-03-31-0.73
Q4 '232023-12-31-0.75
Q3 '232023-09-30-0.69
Q2 '232023-06-30-0.70
Q1 '232023-03-31-0.73
Q4 '222022-12-31-0.77
Q3 '222022-09-30-0.98
Q2 '222022-06-30-0.98
Q1 '222022-03-31-1.00
Q4 '212021-12-311.76
Q3 '212021-09-301.78
Q2 '212021-06-301.67
Q1 '212021-03-311.49
Q4 '202020-12-31-1.41
Q3 '202020-09-30-1.41
Q2 '202020-06-30-1.56
Q1 '202020-03-31-1.49
Q4 '192019-12-31-1.58